SimpleScreen
Provider 
Founded 2014
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public Company
Added
Updated
Freenome offers SimpleScreen
Blood-based cancer screening portfolio covering colorectal and lung tests.
Blood-based cancer screening portfolio covering colorectal and lung tests.
SimpleScreen is Freenome's portfolio of blood-based cancer screening tests, delivered through a standard blood draw and analyzed on the company's multiomics platform. The portfolio's first commercial offering is a colorectal cancer screening test approved by the FDA for average-risk adults aged 45 and older and commercialized in the United States by Abbott.
A lung cancer screening test for high-risk adults who are not participating in recommended screening has received FDA Breakthrough Device Designation and is still in clinical development. The company states that additional cancer screening indications are in development as the portfolio expands.
| Attribute | SimpleScreen | Cologuard Plus | ColoSense | Shield | |
|---|---|---|---|---|---|
| Provider | |  |  |  | |
| Founded | 2014 | 1995 | 2015 | 2011 | |
| Sells To | Enterprise | Consumers, Enterprise | Consumers, Enterprise | Consumers, Enterprise | |
| Pricing Model | Recurring, Software | Recurring, Software | Recurring, Software | Recurring, Software | |
| Ownership | Public Company | Public | Private Equity, Venture Capital | Public |
Provider
Founded 2014
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public Company
Provider
Founded 1995
Sells To Consumers, Enterprise
Pricing Model Recurring, Software
Ownership Public
Provider
Founded 2015
Sells To Consumers, Enterprise
Pricing Model Recurring, Software
Ownership Private Equity, Venture Capital
Provider
Founded 2011
Sells To Consumers, Enterprise
Pricing Model Recurring, Software
Ownership Public